跳至主要内容
临床试验/DRKS00007959
DRKS00007959尚未招募未知

Functional imaging of regional blood flow changes within the tremor network due to Deep Brain Stimulation in the ventrolateral thalamus with H2O-PET - ColTrem II

Department of Neurology, University Hospital of Cologne0 个研究点目标入组 25 人开始时间: 2015年4月7日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 75 Years(—)
性别
All

入选标准

  • ET-patients:
  • Male or female patients with the clinical diagnosis of essential tremor according to the Consensus statement of the Movement Disorder Society on Tremor; ET-Patients aged between 50-75 years; Disease duration of more than 5 years; Capacity for consent so that written informed consent can be achieved; ET-Patients with a formal indication to a treatment with Deep Brain Stimulation (DBS) due to a therapy-refractory manifestation on at least three different pharmaceutical options and with the indication to electrode placement in the ventrolateral thalamus (VLp/Vim); Tolerable tremor severity after switching off the stimulation (DBS-OFF)
  • Control subjects:
  • Subjects aged between 50-75 years; Capacity for consent so that written informed consent can be achieved

排除标准

  • ET-patients:
  • Persons without capacity for consent, minors as well as individuals who are accomodated in an institution due to official or legal regulations; ET-patients suffering from other conditions (e.g. Alzheimer's disease, dystonia, epilepsy) besides essential tremor; ET-pateints with presence of unambiguous unilateral symptoms or hypokinesia; Unilateral dopaminergic deficit in functional imaging (FP-CIT SPECT); ET-patients with a significant response of symptoms after oral administration of levodopa, Irregularities in previous MRI scans (such as e.g. cerebral ischaemia, cerebellar atrophy, head surgery, etc.); Excessive head tremor hampering lying on the back over 90 minutes; Presence of symptomatic tremor causes such as metabolic or psychogenic tremor or due to the intake of tremor facilitating substances/drugs respectively as a consequence of their withdrawal; Presence of life-threatening diseases; Severe psychiatric comorbidities; Pregnant or breastfeeding women; Visual or hearing impairment interfering in the testing; ET-patients taking part in other interventional studies;
  • Control subjects:
  • Persons without capacity for consent, minors as well as individuals who are accomodated in an institution due to official or legal regulations; Subjects suffering from severe neurological disorders; Subjects with a regular intake of drugs interfering with the central nervous system which cannot be discontinued from the evening of the day before the testing until after testing is completed; Presence of life-threatening diseases; Severe psychiatric comorbidities; Pregnant or breastfeeding women; visual or hearing impairment interfering in the testing; Control subjects taking part in other interventional studies;

研究者

发起方
Department of Neurology, University Hospital of Cologne

相似试验